PubMed Health⌕ Search

Biomedical subjects

Abimael D. Rodríguez

Publications and source records attributed to Abimael D. Rodríguez.

4 recordsLinked to original sources
PubMed1998

Unusual Terpenes with Novel Carbon Skeletons from the West Indian Sea Whip Pseudopterogorgia elisabethae (Octocorallia)(1).

From the hexane solubles of the West Indian gorgonian Pseudopterogorgia elisabethae collected near San Andrés Island, Colombia, were isolated a marine diterpenoid, two nor-diterpenoids, and a bisnor-diterpenoid, all of which possess most unusual carbocyclic skeletons. The structures and relative configurations of novel metabolites elisabethins A-C (1-3) and elisabanolide (4) were elucidated by interpretation of overall spectral data, which included 2D NMR correlation methods; IR, UV, and accurate mass measurements (HREIMS); chemical reactions; and X-ray diffraction analyses. One of these, elisabethin B (2), showed significant differential antitumor activity, and compounds 3 and 4 have weak in vitro antituberculosis activity.

Journal Article↗
PubMed1997

The Calyculaglycosides: Dilophol-Type Diterpene Glycosides Exhibiting Antiinflammatory Activity from the Caribbean Gorgonian Eunicea sp.(1)(,)(2).

Three new diterpenoid hexose-glycosides, calyculaglycosides A-C (1-3) were isolated from the Caribbean gorgonian Eunicea sp. Calyculaglycosides A-C are rare diterpene glycosides possessing dilophol (4) aglycones related in biosynthetic origin to the elemene-type glycoside class of potent antiinflammatory agents known as fuscosides. The structures of the new compounds, which were assigned on the basis of spectral studies, were further corroborated by molecular modeling studies. Calyculaglycoside B (2) is an effective topical antiinflammatory agent stronger in potency than the industrial standard indomethacin. Calyculaglycoside B inhibits the synthesis of both prostaglandin PGE(2) and leukotriene LTB(4), suggesting it is a nonselective inhibitor of the 5-lipoxygenase and cyclooxygenase pathways. At concentrations of 10(-4)-10(-5)M, calyculaglycoside B produced LC(50)-level differential responses against a majority of the NCI ovarian cancer lines and several of the renal, prostate, and colon tumor lines.

Journal Article↗